Dr. Alan Mark Smolinski, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 1 Harborside Dr, East Boston, MA 02128 Phone: 617-568-6502 |
Elizabeth Gaskins, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 10 Gove St, East Boston, MA 02128 Phone: 617-569-5800 Fax: 617-568-4780 |
Hang Bich Tran, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 50 Maverick Sq, East Boston, MA 02128 Phone: 617-561-1130 |
Chi Binh Tran, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 50 Maverick Sq, East Boston, MA 02128 Phone: 617-561-1130 |
News Archive
The New York Times reports that the President's inivitation is for a half-day televised summit February 25. It is "a high-profile gambit that will allow Americans to watch as Democrats and Republicans try to break their political impasse." The move is seen as a way for Obama to force Republicans to help govern and to "put more scrutiny on Republican initiatives" on health care.
Scientific Herbal Advances, an applicant for one of the State's five medical marihuana licenses to be awarded by the Department of Health this summer, has received the endorsement of Orange County Executive Steven Neuhaus.
A systematic review of over 50 clinical trials finds that exercise and Vitamin D supplements are the best ways to reduce the risk of falling in people aged 65 and over. The review is published in the December 21 issue of Annals of Internal Medicine and was commissioned by the US Preventive Services Task Force.
Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences and nanotechnology technology leader, announces that on September 11th, 2009 Arrayit delivered its proprietary nanotechnology platform to Sandia National Laboratories in Albuquerque, New Mexico. Sandia Labs, managed by the Lockheed Martin Corporation, works with the Transportation Security Administration (TSA) and the Department of Homeland Security to enhance national security.
XenoPort, Inc. announced today that it has discovered a novel prodrug that has the potential to improve significantly the blood concentration of acamprosate compared with the currently approved formulation of acamprosate. Preclinical data on this new product candidate will be presented tomorrow at the National Fragile X Foundation's 12th International Fragile X Conference in Detroit, Michigan.
› Verified 9 days ago